Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Outlook Therapeutics, Inc.

Market Cap 190M 164M 151M 141M 265M 17.94B 268M 1.78B 693M 8.79B 712M 697M 30.45B P/E 2026 *
-3.02x
P/E 2027 * -5.96x
Enterprise Value 190M 164M 151M 141M 265M 17.94B 268M 1.78B 693M 8.79B 712M 697M 30.45B EV / Sales 2026 *
158x
EV / Sales 2027 * 4.15x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day+3.50%
1 week+122.79%
Current month+115.07%
1 month+588.29%
3 months+346.15%
6 months-36.44%
Current year-0.63%
1 week 0.93
Extreme 0.928
1.58
1 month 0.22
Extreme 0.215
1.58
Current year 0.16
Extreme 0.1611
1.58
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 30/06/2025
Chief Executive Officer 60 02/12/2024
Chief Tech/Sci/R&D Officer - 18/01/2023
Director TitleAgeSince
Director/Board Member 60 01/08/2018
Director/Board Member 65 10/12/2015
Chairman 41 30/01/2025
Date Insider Type Main position Quantity % Market Cap.
06-01Buy

Director

29,000 0.0181%
05-27
Gms Ventures & Investments
BuyCompany 39,516,849 24.6751%
05-26Buy

Chairman

122,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
+35.34%+122.79%-11.30%-95.66% 190M
-0.63%-1.56%-12.25%-10.53% 43.51B
-2.17%+4.70%+293.71%+535.99% 33.29B
-1.60%-1.58%-0.19%+31.82% 29.34B
+0.44%-3.80%+12.51%-17.06% 29.9B
-0.29%+2.65%+13.24%+21.04% 25.42B
+3.54%+8.43% - - 14.36B
-1.26%-1.11%+53.37%+108.10% 13.18B
-1.18%-5.26%+2.21%+3.30% 12.72B
-1.18%-2.00%+107.41%+78.18% 12.08B
Average +0.16%+12.81%+50.97%+72.80% 21.4B
Weighted average by Cap. -0.25%+0.74%+59.99%+103.87%

Financials

2026 *2027 *
Net sales 1.2M 1.03M 952K 894K 1.68M 113M 1.7M 11.25M 4.38M 55.56M 4.5M 4.41M 193M 45.73M 39.41M 36.29M 34.07M 63.97M 4.32B 64.64M 429M 167M 2.12B 172M 168M 7.34B
Net income -53.44M -46.05M -42.4M -39.81M -74.75M -5.05B -75.54M -501M -195M -2.47B -201M -196M -8.57B -35.55M -30.63M -28.21M -26.49M -49.73M -3.36B -50.25M -333M -130M -1.65B -133M -131M -5.7B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
17/06/26 1.550 $ -1.27% 3,911,430
16/06/26 1.570 $ +35.34% 42,831,636
15/06/26 1.160 $ -4.92% 23,474,993
12/06/26 1.220 $ +10.91% 38,103,435
11/06/26 1.100 $ +23.60% 43,930,129
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.570USD
Average target price
5.500USD
Spread / Average Target
+250.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!